John Milligan compensation by year
GILEAD SCIENCES Summary Compensation Table · all 3 fiscal years held| Component | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Salary | $1,465,385 | $1,539,462 | $1,581,623 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $4,349,750 | $4,894,499 | $9,865,666 |
| Option awards | $5,500,077 | $5,749,998 | $11,131,386 |
| Non-equity incentive | $2,610,000 | $3,244,500 | $3,341,100 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $10,000 | $10,000 | $42,056 |
| Total | $13,935,212 | $15,438,459 | $25,961,831 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GILEAD SCIENCES, INC. DEF 14A filed March 25, 2019, accession 0001206774-19-001013, and prior-year filings. Open the filing on EDGAR.
How this page was built: the GILEAD SCIENCES, INC. filed document, accession 0001206774-19-001013. Every figure is read from that document and cited to the page and table it appears in. Filed March 25, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 26,528 | $1,659,326 | — |
| RSU | 21,814 | $1,364,466 | — |
| RSU | 21,672 | $1,355,584 | — |
| RSU | 19,162 | $1,198,583 | — |
| RSU | 17,820 | $1,114,641 | — |
| RSU | 10,604 | $663,280 | — |
| RSU | 8,617 | $538,993 | — |
| PSU | 9 | $563 | — |
| PSU | 7 | $438 | — |
| Option | 73,694 | — | $84.05 |
| Option | 4,394 | — | $104.83 |
| Option | 295,660 | — | $83.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in GILEAD SCIENCES, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
GILEAD SCIENCES’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| John Milligan · this page | President and Chief Executive Officer | $25,961,831 |
| Laura Hamill | Former Executive Vice President Worldwide Commercial Operations | $10,337,826 |
| John McHutchison | Former Chief Scientific Officer, Head of Research and Development | $7,274,972 |
| Robin Washington | Former Executive Vice President, Chief Financial Officer | $6,342,671 |
| Gregg Alton | Chief Patient Officer | $4,906,863 |
The full GILEAD SCIENCES compensation record
free company briefThis page is one person within GILEAD SCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the GILEAD SCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GILEAD SCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.